Overview
| Details
Timely participation
in clinical trials is vital – delays are costly to sponsors and to patients.
If patients fail to sign on in adequate numbers ...
the assessment of the therapy will not be made
no matter how well the study is designed from the point of view of regulators and scientists.
Indeed, the urgency of our situation requires that the evaluation system
becomes as efficient as it can be.
Resulting
in efficiency and faster accrual
We
prepare continuously by reviewing reputable
materials on drug development
and assessment, and by seeking guidance
from our scientific advisors.
Importantly, to minimize bias, our policy is to accept no funding from
commercial entities that market drugs or health supplements.
We are committed to:
